Nimble Therapeutics and RayzeBio today announced the companies have entered a strategic collaboration to discover and develop novel peptide-based radiopharmaceuticals for the treatment of cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210628005106/en/
“We are excited to welcome RayzeBio to our growing family of partners,” said Jigar Patel, Ph.D., CEO of Nimble Therapeutics. “Through our pioneering work, we have built a platform to rapidly identify drug-like hits and optimize them into leads, and conduct elaborate medicinal chemistry campaigns to engineer candidates with optimal potency, selectivity, stability, and other important attributes. This agreement with RayzeBio underscores the value inherent in Nimble’s platform to advancing the radiopharmaceutical field.”
“Nimble’s platform technology is promising,” said Ken Song, M.D., CEO of RayzeBio. “Nimble’s rational approach to using its platform to identify novel peptide-like molecules allows us to further expand our radiopharmaceutical pipeline and pursue multiple therapeutic programs in parallel.”
Under the terms of the agreement, Nimble will receive an undisclosed upfront payment, research reimbursements and may also receive further milestone payments and royalties on sales of resulting products. RayzeBio has exclusive rights to develop and commercialize peptides discovered under the collaboration, and an option to further expand the collaboration to include additional targets.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace
